maximum

Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial

FREMONT, Calif., Nov. 8, 2016 /PRNewswire/ — Asterias Biotherapeutics, Inc. (NYSE MKT: AST), a biotechnology company pioneering the field of regenerative medicine,…